Class IIa recommendation provided for maintenance use of Effient in ACS-PCI STEMI and NSTE-ACS patients who are not at high risk for bleeding complications and who do not have a history of stroke or transient ischemic attack
New 2016 ACC/AHA Guideline Focused Update States that it is Reasonable to Choose Effient® (prasugrel) Over Clopidogrel for Certain ACS-PCI Patients with ST-Elevation Myocardial Infarction and NSTE-ACS (NYSE:LLY)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.